Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05805072
Other study ID # Selinexor+HAAG+HMA
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 1, 2023
Est. completion date June 30, 2024

Study information

Verified date March 2023
Source The First Affiliated Hospital of Soochow University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of selinexor and HAAG +/- HMA in relapsed/refractory acute leukemia (AML) patients.


Description:

This protocol corresponds to a single-center, open-label, single-arm, exploratory study designed to determine the efficacy and safety of the combination of selinexor with HAAG +/- HMA in patients with relapsed or refractory AML. The patients who respond to this combination treatment will undergo allogeneic hematopoietic stem cell transplantation and post-transplantation maintenance treatment according to patient's wishes. Each cycle of treatment will compromise 2 weeks of selinexor treatment, and at least two weeks off treatment. The new cycle will not start if there is an ongoing grade 3 or higher non-hematologic toxicity or persistent grade 3 neutropenia in patients achieving CR. Study design allows 20 patients. Treatment will consist of selinexor 60 mg/day orally on d1,4,8,11, HHT 1 mg/day intravenously on days 3 to 9, cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9, aclacinomycin 10 mg/day intravenously on days 3 to 6, G-CSF 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram, DAC 20 mg/m2/day intravenously on days 1 to 5. Whether to add hypomethylating agents was decided by the investigator according to the patient's disease degree and tolerance status. If patients had previously been exposed to decitabine, azacitidine will added this regimen, AZA 20 mg/m2/day subcutaneously on days 1 to 7.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Men and women aged =18 years. 2. Diagnosis of AML (defined according to the 5th of the World Health Organization [WHO] 2022 criteria) of any type except for acute promyelocytic leukemia (APL; AML M3)and the following conditions were met: Relapsing or refractory AML 3. Eastern Cooperative Oncology Group (ECOG) performance status of = 2. 4. Female patients of child-bearing potential must have a negative serum pregnancy test at screening and agree to use two reliable methods of contraception for six months after their last dose of medication. 5. Patients whose expecting survival time will be more than 3 months. 6. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures. Exclusion Criteria: 1. AML transformed from chronic myeloid leukemia. 2. Patients with APL/AML M3. 3. Presence of CNS leukemia. 4. Uncontrolled infection or other serious disease. 5. Unstable cardiovascular function: Cardiac ejection fraction (EF)<0.5, or congestive heart failure (CHF) of NYHA Class = 2. 6. Unstable Liver and kidney function:TBLL=2.0 mg/dl, AST=3×ULN, Ccr=50 ml/min, SpO2<92%. 7. Known human immunodeficiency virus (HIV) infection. 8. Active hepatitis B or hepatitis C infection. 9. Pregnant and lactating women. Patients with other commodities that the investigators considered not suitable for the enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Selinexor
Selinexor 60 mg/day, orally on d1,4,8,11
Homoharringtonine
Homoharringtonine 1 mg/day intravenously on days 3 to 9
Cytarabine
cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
Aclacinomycin
aclacinomycin 10 mg/day intravenously on days 3 to 6
Granulocyte Colony-Stimulating Factor
granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
Decitabine
Decitabine 20 mg/m2/day intravenously on days 1 to 5.
Azacitidine
Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7

Locations

Country Name City State
China The First Affiliated Hospital of Soochow University Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With CR/CRi Number of Participants With CR/CRi
CR: Absolute Neutrophil count (ANC) >1.0x10^9/L, Platelet count >100x10^9/L, Bone marrow blasts <5%, no Auer rods, no evidence of extramedullary disease.
CRi: Same as CR, but ANC may be <1.0x10^9/L and/or Platelet count <100x10^9/L
End of cycle 1 and 2 (each cycle is 28 days)
Secondary Number of Participants With ORR ORR =CR+CRi+PR+MLFS
PR: Absolute Neutrophil count (ANC) >1.0x10^9/L, Platelet count >100x10^9/L, at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts <5% with persistent Auer rods.
MLFS: Bone marrow blasts <5%, no Auer rods, no evidence of extramedullary disease
End of cycle 1 and 2 (each cycle is 28 days)
Secondary Percentage of Patients Transplanted After Induction Therapy (Stem Cell Transplantation) Rate of ASCT: Percentage of patients being transplanted after induction therapy (stem cell transplantation) 1-2 induction cycles (4 - 8 weeks)
Secondary Progression-Free Survival Progression-free survival (PFS): was calculated from the time of informed consent to the date of recurrence or death, whichever occurred first. Patients were censored at the date of the last follow-up visit if they were alive without relapse.
Disease progression was defined as presence of >50% increase in bone marrow blasts to a level of at least 50% and/or a doubling of the percentage of peripheral blood blasts to a level of at least 50%.
Time from registration to event, max 2 years
Secondary Overall Survival Overall survival (OS) was calculated from the date of informed consent to the date of death. Patients still alive at the end of follow-up were censored at the last date of follow-up. Time from registration to event, max 2 years
Secondary Number of adverse events Adverse events are evaluated with CTCAE V5.0 End of cycle 1 and 2 (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Completed NCT01258816 - The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) Phase 1
Terminated NCT02520427 - A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies Phase 1
Recruiting NCT05054543 - Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML Phase 3
Completed NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Phase 1
Recruiting NCT05428969 - A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) Phase 1/Phase 2
Recruiting NCT04839341 - Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients Phase 1
Recruiting NCT03631576 - CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001) Phase 2/Phase 3